- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Fiasp®, Novolog®, 670G hybrid closed loop continuous subcutaneous insulin infusion system
- Drug · Device
- Lead sponsor
- Texas Diabetes & Endocrinology, P.A.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 670G hybrid closed loop continuous subcutaneous insulin infusion system Clear all
- Conditions
- Type 1 Diabetes
- Interventions
- 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 959 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 25
- States / cities
- La Jolla, California • Palo Alto, California • Sacramento, California + 21 more